📊 VTAK Key Takeaways
Is Catheter Precision, Inc. (VTAK) a Good Investment?
Catheter Precision exhibits severe financial distress with only $88K in cash reserves against an $8.3M quarterly operating cash burn, creating an imminent liquidity crisis that threatens solvency without immediate capital infusion. While the 95% revenue growth and 92.3% gross margin demonstrate product-market viability, the company's operating losses remain unchanged YoY at -$21.1M, indicating unsustainable fixed cost structure with no credible path to profitability. The 0.10x current ratio indicates the company cannot meet short-term obligations, making this a distressed situation with extreme execution risk.
Why Buy Catheter Precision, Inc. Stock? VTAK Key Strengths
- Revenue growth of 95% YoY shows strong market demand for the surgical device
- Exceptional gross margin of 92.3% demonstrates strong pricing power and product efficiency
- Reasonable debt-to-equity ratio of 0.44x indicates leverage is not structurally problematic
VTAK Stock Risks: Catheter Precision, Inc. Investment Risks
- Critical liquidity crisis: $88K cash with $8.3M quarterly operating cash burn results in <1 month runway
- Current ratio of 0.10x indicates inability to meet short-term obligations; insolvency risk is acute
- Operating losses unchanged YoY despite 95% revenue growth; no credible path to profitability evident
- Company is pre-cash-flow positive pre-revenue stage with massive unfunded operating requirements
Key Metrics to Watch
- Quarterly cash balance and burn rate trajectory
- Capital raise announcements or financing activities
- Quarterly revenue run-rate and product commercialization progress
- Operating expense reduction initiatives
- Form 8-K filings for going concern warnings or restructuring events
Catheter Precision, Inc. (VTAK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
VTAK Profit Margin, ROE & Profitability Analysis
VTAK vs Healthcare Sector: How Catheter Precision, Inc. Compares
How Catheter Precision, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Catheter Precision, Inc. Stock Overvalued? VTAK Valuation Analysis 2026
Based on fundamental analysis, Catheter Precision, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Catheter Precision, Inc. Balance Sheet: VTAK Debt, Cash & Liquidity
VTAK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Catheter Precision, Inc.'s revenue has declined by 89% over the 5-year period, indicating business contraction. The most recent EPS of $-248.22 indicates the company is currently unprofitable.
VTAK Revenue Growth, EPS Growth & YoY Performance
VTAK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $96.0K | -$2.3M | $-1.70 |
| Q2 2025 | $93.0K | -$4.2M | $-0.38 |
| Q1 2025 | $82.0K | -$2.7M | $-0.36 |
| Q1 2023 | $9.0K | -$5.5M | N/A |
| Q3 2022 | $5.0K | -$4.3M | $-4.36 |
| Q2 2022 | $5.0K | -$5.2M | $-0.26 |
| Q1 2022 | $4.0K | -$5.5M | N/A |
| Q3 2021 | $5.0K | -$4.3M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Catheter Precision, Inc. Dividends, Buybacks & Capital Allocation
VTAK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Catheter Precision, Inc. (CIK: 0001716621)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VTAK
What is the AI rating for VTAK?
Catheter Precision, Inc. (VTAK) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VTAK's key strengths?
Claude: Revenue growth of 95% YoY shows strong market demand for the surgical device. Exceptional gross margin of 92.3% demonstrates strong pricing power and product efficiency.
What are the risks of investing in VTAK?
Claude: Critical liquidity crisis: $88K cash with $8.3M quarterly operating cash burn results in <1 month runway. Current ratio of 0.10x indicates inability to meet short-term obligations; insolvency risk is acute.
What is VTAK's revenue and growth?
Catheter Precision, Inc. reported revenue of $819.0K.
Does VTAK pay dividends?
Catheter Precision, Inc. does not currently pay dividends.
Where can I find VTAK SEC filings?
Official SEC filings for Catheter Precision, Inc. (CIK: 0001716621) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VTAK's EPS?
Catheter Precision, Inc. has a diluted EPS of $-25.98.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VTAK a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Catheter Precision, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VTAK stock overvalued or undervalued?
Valuation metrics for VTAK: ROE of -243.6% (sector avg: 15%), net margin of -2,098.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VTAK stock in 2026?
Our dual AI analysis gives Catheter Precision, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VTAK's free cash flow?
Catheter Precision, Inc.'s operating cash flow is $-8.3M, with capital expenditures of $17.0K. FCF margin is -1,015.0%.
How does VTAK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,098.0% (avg: 12%), ROE -243.6% (avg: 15%), current ratio 0.10 (avg: 2).